ClinicalTrials.gg
RecruitingNCT06099717T-bridgeUpdated Oct 23, 2026

Clinical Performance of Dual-cantilevered Single-implant Bridge

An interventional study of Dual-cantilevered implant bridge and 3-unit iFDP in Dental Implant Failed, sponsored by University of Bern. Recruiting at 1 site in Brazil. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by University of Bern · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 4 months later.
Updated Oct 23, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study aims to evaluate the clinical performance (implant and prosthetic survival/ success rates) of a novel implant-supported fixed dental prosthesis design: the dual-cantilevered single implant bridge (T-Bridge) made out of monolithic zirconia bonded to a titanium base abutment (Variobase abutments)

02

Conditions studied

  • Dental Implant Failed

Keywords

  • Dental implant
03

In context

Lead sponsor

University of Bern is the lead sponsor of 209 studies on the registry; 46 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 20 years
  • Willingness to sign an and participate in the study
  • Three missing adjacent teeth in the posterior site.
  • Tooth gap of 21-24 mm.
  • Presence of natural or artificial opposing dentition
  • Sufficient vertical interocclusal space of an implant restoration (7mm)
  • Sufficient ridge height to place an implant of 10mm in length
  • Sufficient ridge width for the placement of a 4.1mm diameter implant. Simultaneous GBR to achieve a width of 6.5mm will be included.

Exclusion criteria

Exclusion Criteria:

  • Any physical or mental disorder that would interfere with the ability to perform adequate oral hygiene or the capability of providing written and compliance with the protocol
  • Any disorder that would interfere with wound healing or represent a for implant surgery, such as but not limited to uncontrolled diabetes or conditions resulting in or requiring , radiation, chemotherapy, frequent use of antibiotics or antiresorptive medication such as bisphosphonates.
  • Pregnancy or lactation
  • Heavy smoking habit with ≥ 10 cig/d
  • Severe bruxism or clenching habits, presence of oro-facial pain
  • Insufficient ridge width/height for the study implant
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Test

    Dual-cantilevered single implant bridge

    Device: Dual-cantilevered implant bridge

  • Active comparator
    Control

    3-unit implant fixed dental prosthesis

    Device: 3-unit iFDP

Interventions

  • DeviceDual-cantilevered implant bridge

    A 3-unit supported by one implant in the middle

  • Device3-unit iFDP

    3-unit fixed dental prosthesis supported by two implants

06

What researchers measure

Primary outcomes

  1. Implant and prosthetic success

    Primary outcome parameter: implant and prosthetic success Implant success and survival rate will be defined according to established criteria (Buser et al. 1991): A surviving implant and/or restoration is defined as are in place at the time of the follow-up.

    Time frame: 10 years

  2. Implant and prosthetic survival

    Implant success and survival rate will be defined according to established criteria (Buser et al. 1991): A surviving implant and/or restoration is defined as are in place at the time of the follow-up.

    Time frame: 10 years

Secondary outcomes

  1. Implant and prosthetic complications

    Biological and/or Technical Implant and prosthetic complications

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Aug 2026 → Dec 2026 and completion Oct 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2023
First posted
Oct 25, 2023
StartActual
Jun 30, 2024
Primary completionEst.
Dec 2026was Aug 2026
CompletionEst.
Dec 2026was Oct 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→Dec 2026
Oct 23, 2026
Study completion
Oct 2026→Dec 2026
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Primary completion Aug 2026→Dec 2026
    Study completion Oct 2026→Dec 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06099717
Lead sponsor
University of Bern
Collaborators
ITI International Team for Implantology, Switzerland
Responsible party
Sponsor
First posted
Oct 25, 2023
Start date
Jun 30, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 23, 2026

Study contacts

Manrique Fonseca, Dr
Contact
manrique.fonseca@unibe.ch
+416840630
Martin Schimmel, Prof
study chair · University of Bern

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion